dehydroepiandrosterone has been researched along with Triple Negative Breast Neoplasms in 3 studies
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.
Triple Negative Breast Neoplasms: Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The present study aimed to elucidate the effects of PU-H71 combined with DHEA on triple-negative breast cancer cell line MDA-MB-231 and to assess the synergy using the Chou-Talalay method." | 1.56 | Heat shock protein 90α inhibitor, PU-H71 in combination with DHEA promoting apoptosis in triple-negative breast cancer cell line MDA-MB-231. ( El-Nikhely, N; Eldemellawy, M; Elkewedi, M; Hassan, M; Saeed, H; Shalaby, M; Soudan, H, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Luo, M | 1 |
| Fu, A | 1 |
| Wu, R | 1 |
| Wei, N | 1 |
| Song, K | 1 |
| Lim, S | 1 |
| Luo, KQ | 1 |
| Soudan, H | 1 |
| Saeed, H | 1 |
| Eldemellawy, M | 1 |
| Shalaby, M | 1 |
| Hassan, M | 1 |
| Elkewedi, M | 1 |
| El-Nikhely, N | 1 |
| Pietri, E | 1 |
| Massa, I | 1 |
| Bravaccini, S | 1 |
| Ravaioli, S | 1 |
| Tumedei, MM | 1 |
| Petracci, E | 1 |
| Donati, C | 1 |
| Schirone, A | 1 |
| Piacentini, F | 1 |
| Gianni, L | 1 |
| Nicolini, M | 1 |
| Campadelli, E | 1 |
| Gennari, A | 1 |
| Saba, A | 1 |
| Campi, B | 1 |
| Valmorri, L | 1 |
| Andreis, D | 1 |
| Fabbri, F | 1 |
| Amadori, D | 1 |
| Rocca, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Non Randomized Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)[NCT02000375] | Phase 2 | 20 participants (Actual) | Interventional | 2013-03-31 | Terminated (stopped due to Due to slow recruitment and recent new published data) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for dehydroepiandrosterone and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aroma | 2019 |
2 other studies available for dehydroepiandrosterone and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
High Expression of G6PD Increases Doxorubicin Resistance in Triple Negative Breast Cancer Cells by Maintaining GSH Level.
Topics: Animals; Antioxidants; Cell Line, Tumor; Dehydroepiandrosterone; Doxorubicin; Glucosephosphate Dehyd | 2022 |
Heat shock protein 90α inhibitor, PU-H71 in combination with DHEA promoting apoptosis in triple-negative breast cancer cell line MDA-MB-231.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzodioxoles; Caspases; CDC2 Protein Kin | 2020 |